Algorae Pharmaceuticals (ASX:1AI) has agreed with the Victorian Centre for Functional Genomics (‘VCFG’) at Peter MacCallum Cancer Centre to validate AI-predicted drug synergies through high-throughput screening.
The study will evaluate 24 drug candidates, 21 wholly AI-generated, using VCFG’s advanced screening platform, which includes proprietary high-throughput technologies and synergy assessment methodologies.
Algorae said the collaboration is designed to confirm the efficacy of drug combinations across four distinct cancer cell lines, including glioblastoma, pancreatic ductal adenocarcinoma, invasive breast carcinoma and prostate carcinoma.
Algorae said the partnership with VCFG is an important step in validating its AI-driven approach to drug discovery.
The Algorae Operating System (‘AlgoraeOS’), developed in collaboration with UNSW AI Institute and supported by CSIRO funding, has predicted novel drug interactions. The preclinical screening will empirically test the AlgoraeOS predictions and provide essential data to support regulatory and commercial pathways.
"This agreement with Peter Mac marks a significant milestone for Algorae," said David Hainsworth, executive chairman of Algorae Pharmaceuticals. "By leveraging Artificial Intelligence to predict synergistic drug interactions we are endeavouring to accelerate the drug discovery process and expand our pipeline. We’re excited to collaborate with a premier cancer research institution to validate our findings."